Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Purpose Canadian Financial Income Series A T.BNC

The fund seeks to provide shareholders with (i) long-term capital appreciation through investment in a portfolio of Canadian Banks (defined below) (up to 70% on an equal weighted basis) and Canadian Insurance Companies (defined below) (up to 30% on an equal weighted basis) and (ii) monthly distributions.To achieve its investment objectives, the fund will invest primarily in equity securities of... see more

TSX:BNC - Post Discussion

Purpose Canadian Financial Income Series A > Latest Treatment AUA Guideline for NMIBC...
View:
Post by rgonlyfactspls on Sep 12, 2016 5:15pm

Latest Treatment AUA Guideline for NMIBC...

Just crossed my screen - October issue of Journal of Urology. Am I reading this correctly!?!?!...See point 26 below....one of two solutions for High Risk NMI bladder cancer patients where cancer persists or is recurrent (after two courses of BCG) and these patients are unwilling or unfit for cystectomy is RECOMMEND ENROLLMET IN A CLINICAL TRIAL. i.e....gamble with an UNPROVEN clinical trial??? So, the FDA turned down MCNA but this is a "formal" RECOMMENDATION??? Source - Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline The Journal of Urology: Oct-2016 (Volume 196, Issue 4) EXCERPT - 26. In a patient with persistent or recurrent intermediate- or high-risk NMIBC who is unwilling or unfit for cystectomy following two courses of BCG, a clinician may recommend clinical trial enrollment. A clinician may offer this patient intravesical chemotherapy when clinical trials are unavailable. (Expert Opinion). https://www.jurology.com/article/S0022-5347(16)30629-2/fulltext?elsca1=etoc&elsca2=email&elsca3=0022-5347_201610_196_4_&elsca4=Urology
Comment by terr2 on Sep 12, 2016 5:45pm
Are we getting skrewed over again?
Comment by Jasl on Sep 14, 2016 9:50am
Should have been MCNA. Too bad on the timing of this recommendation. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities